🏛️ Verified NIH Record • Updated 2025-03-12
Infant Mortality Reduction by the Mass Administration of Azithromycin (NCT04716712)
Mortalite Infantile Reduite Par l'Administration de Masse de l'Azitromycine
🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: University of California, San Francisco
🩺 Plain-English Summary (8th-Grade Level)
This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 1 Month to 11 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of California, San Francisco — San Francisco, California
- Centre de Recherche en Sante de Nouna — Nouna,
- Helen Keller International — Ouagadougou,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Child Mortality clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.